Cyclacel Pharmaceuticals announced on February 26, 2025, that it regained compliance with Nasdaq's equity requirement and appointed Datuk Dr. Doris Wong Sing Ee as the new CEO, while David Lazar resigned from his positions. The company also entered into a settlement agreement with a resigning director and completed a securities purchase agreement resulting in significant changes in its capital structure.